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Background: Cognitive impairment and Alzheimer’s disease (AD) are increasingly considered a major public health
problem. The MemoVie cohort study aims to investigate the living conditions or risk factors under which the
normal cognitive capacities of the senior population in Luxembourg (≥ 65 year-old) evolve (1) to mild cognitive
impairment (MCI) – transitory non-clinical stage – and (2) to AD. Identifying MCI and AD predictors undeniably
constitutes a challenge in public health in that it would allow interventions which could protect or delay the
occurrence of cognitive disorders in elderly people. In addition, the MemoVie study sets out to generate hitherto
unavailable data, and a comprehensive view of the elderly population in the country.
Methods/design: The study has been designed with a view to highlighting the prevalence in Luxembourg of MCI
and AD in the first step of the survey, conducted among participants selected from a random sample of the
general population. A prospective cohort is consequently set up in the second step, and appropriate follow-up of
the non-demented participants allows improving the knowledge of the preclinical stage of MCI. Case-control
designs are used for cross-sectional or retrospective comparisons between outcomes and biological or clinical
factors. To ensure maximal reliability of the information collected, we decided to opt for structured face to face
interviews. Besides health status, medical and family history, demographic and socio-cultural information are
explored, as well as education, habitat network, social behavior, leisure and physical activities. As multilingualism is
expected to challenge the cognitive alterations associated with pathological ageing, it is additionally investigated.
Data relative to motor function, including balance, walk, limits of stability, history of falls and accidents are further
detailed. Finally, biological examinations, including ApoE genetic polymorphism are carried out. In addition to
standard blood parameters, the lipid status of the participants is subsequently determined from the fatty acid
profiles in their red blood cells. The study obtained the legal and ethical authorizations.
Discussion: By means of the multidisciplinary MemoVie study, new insights into the onset of cognitive impairment
during aging should be put forward, much to the benefit of intervention strategies as a whole.
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Given longer life expectancy along with the lack of efficient
therapeutic strategies, cognitive disorders and Alzheimer’s
disease (AD) are increasingly considered a major public
health problem. The cost of these pathologies represents an
important burden for public health policies. Some projec-
tions venture a worldwide figure of 81.1 million people
affected by dementia by 2040, providing no curative treat-
ment is developed by then [1]. Therefore, better
characterization of the preclinical stage of AD has been a
crucial challenge for research over the past 10 years. This
appears to be the stage at which prevention strategies
should prove most efficient in delaying or even avoiding
further cognitive decline. From this background emerged
the concept of mild cognitive impairment (MCI), advocated
by Petersen and co-workers [2]. In spite of the controversy
surrounding this concept, it was observed that people who
meet the criteria for MCI are likely to progress to dementia
at a rate of approximately 12% per year, compared to 1 to
2% for cognitively normal people at the same age [2,3]. The
MCI criteria are based on the following decision process: a)
A cognitive complaint, preferably corroborated by an
informant; b) Essentially normal general cognition, but a
deficit in at least one cognitive task considering perfor-
mances adjusted for age and education level; c) No demen-
tia according to the approved Diagnostic and Statistical
Manual of Mental Disorders (DSM) IV criteria; d) Argu-
ments for a cognitive decline, without consequences on
daily life activities or with minimal discomfort on accom-
plishing complex instrumental activities.
Up to now, few studies have explored MCI in healthy
people from the general population, and the most recent
results have shown the difficulty in approaching MCI
prevalence, which obviously vary considerably according
the criteria applied [4]. The complexity also lies in the fact
that a spontaneous complaint is difficult to estimate [5].
Moreover, no national statistics on AD are available in
Luxembourg, let alone on MCI. In line with the EU re-
search program on “medical and social challenges posed
by an ageing population and the disabilities associated
with old age” (Official Journal of 15 November 2000),
the National Fund for Research (FNR), which is the in-
stitution that provides financial support to research in
Luxembourg, has set up a specific research program.
This program aimed to study the epidemiological, psy-
chosocial and biological aspects of the neurodegenera-
tive diseases of old age in the country and to obtain a
comparative view of these aspects with the broader
European context. The national approach adopted is a
holistic one, i.e. multidisciplinary and multidimensional,
giving priority to projects which are interactive. The
MemoVie study started in 2008, federating scientists,
physicians, nurses, neuro-psychologists and statisticians
in Luxembourg within a “research consortium”.Objectives
Based on an interdisciplinary approach, the MemoVie study
has the ambition to consider the problems of cognitive dis-
orders in elderly subjects from different viewpoints. Since
no previous overview of these concerns for Luxembourg is
available, the first goal of the present study is to provide the
national prevalence of subjects suffering from MCI and
from AD as well as to identify the “environmental” condi-
tions and biological factors in association with the occur-
rence of MCI and their evolution to AD.
The “environmental” conditions to be examined are
demographic and socio-cultural parameters. Among these
socio-cultural parameters, special consideration is given to
multilingualism, an aspect of particular importance in
Luxembourg since residents practice almost 3 languages
on average. Sub-clinical impairments are explored by
assessing basic general data, by evaluating cardiovascular
risk factors, cardiovascular events, the presence of meta-
bolic disorders (e.g. known and sub-clinical diabetes melli-
tus), the long-term intake of medications that may impact
on cognition and major current comorbidities. Biological
factors examined also include the study of APOE4 gene
polymorphism, blood protein patterns, and selected blood
lipid components. Using non-invasive methods, as well as
non-hospital environment, the comprehensive approach
proposed in this project should allow studying how these
factors and parameters are associated with the MCI stage
and its evolution to AD, further exploring the potential
interactions that could occur.
Methods/design
Study design and sampling frame
Since one of the aims of the MemoVie project is to explore
the national prevalence of AD and of MCI, it appears cru-
cial to set up at baseline a representative cohort of the
senior population in the country. After stratification by age
group and gender, potential participants were randomly
selected out of any hospital environment from the national
social insurance register covering about 97% of the total
population. The General Inspectorate of Social Security or
IGSS register helped to construct the initial sampling
frame, by selecting Luxembourg residents aged over 64 on
January 1st 2008 and providing their address, according to
our criteria. These addresses can possibly be those of care
homes, when people have already been institutionalized.
The participants need to be followed up in order to provide
information on the possible evolution from normal cogni-
tive status to MCI and from MCI to AD. Additional spon-
taneous volunteers (obviously not to be considered in the
prevalence study) are concomitantly included in the co-
hort. Therefore, the cohort is continuously fed in a
dynamic way with regular inclusions of new volunteers.
The general format of the project is that of a prospective
cohort, combined with nested case-control studies. Such a
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accordance with the research question, with no need to
conduct these items on all subjects included in the cohort.
The nested design strengthens the investigations of the
considered outcomes of persons suffering from MCI, AD
and cognitively normal people, while reducing the costs of
the study.
Sample size and power estimation
The global format of the study is divided into two parts:
– The first one consists in the prevalence study of MCI
and AD in Luxembourg considering an expected
prevalence of persons with MCI of approximately
20% in the general population aged over 65 or 70
[6-8] and a 2 to 5% prevalence of persons suffering
from a sporadic form of AD [9]. Therefore, with a
precision of 2.5%, a sample size of 983 is computed
with a power of 95% and an alpha risk of 5%. This
sample size also offers the opportunity to investigate
AD prevalence. The calculation for the latter
required a sample size of 753 with a precision of 1%,
a power of 95% and an alpha risk of 5%. Assuming
40% of refusal to participate, the sample size
amounts to 1377 persons. In addition, this first
prevalence study allows setting up the MemoVie
cohort.
At the end of the prevalence evaluation, the global
sample is expected to be constituted with groups of par-
ticipants defined as “cognitively normal”, “MCI” and
“persons with probable AD” in frequencies of about 780,
200 and 20 respectively. At this stage, comparison is
drawn in a case-control assessment between the groups
according to the different parameters. Power calculations
show that a group of 200 MCI subjects and 200 control
subjects yields statistically significant odds ratio of 2.3
(alpha error 5% and 80% power).
– The second part of the project consists in the
prospective cohort of people aged over 64 years who
presented normal cognition or MCI. Participants
with AD at baseline are not further followed up. The
cohort leads to comparative analysis between the
main outcomes, i.e. evolution from normal cognitive
capacities to MCI and evolution from MCI to AD
(Figure 1). We adopt as initial (pessimistic)
assumption 12% of MCI subjects likely to progress
to AD in the course of 3 years. A studied
characteristic present in 25% of MCI subjects is
supposed to be associated with a 30% chance of
3-year progression to AD. Then, given the 200 MCI
subjects, the statistical significance of a relative risk
of 3.0 could be shown in this study.Recruitment procedure
Before sending individual invitation letters, several strat-
egies are used to enhance participation in the project: 1)
The study is advertised in the local newspapers in order to
inform the general population, and thereby create aware-
ness; 2) All physicians whose practice could mainly target
the elderly (general practitioners, internists, neurologists,
psychiatrists and physicians specialized in reeducation and
functional rehabilitation) received a letter and a USB key
containing a personalized letter with a description of our
approach, the summary of the project, the composition of
its research team, its partners and the information note
accompanying the informed consent given to participants.
The purpose was to inform health professionals about our
study, its objectives and issues, in case some of their
patients were selected and wished to discuss the project
and collect their views.
The inclusion criteria imposed at baseline are: to
reside in Luxembourg and to be aged at least 65 years.
Exclusion criteria are the conditions that may prevent
the neuropsychological evaluation i.e. non- or poorly
sighted, and people speaking none of the proposed lan-
guages: i.e. official and practiced languages in the coun-
try such as Luxembourgish, French, German, English,
Portuguese and Italian.
The recruited seniors are sent a letter of invitation that
described the study and set out its purpose and scope.
Invited persons are given the opportunity to accept or
decline participation by returning the reply coupon in a
prepaid envelope. One week after the mailing, subjects
who have not mailed back the reply coupon, as well as
those who have agreed to participate, receive a telephone
call from a trained assistant. The telephone interview
aims at describing the study one more time, giving
people the opportunity to ask questions, stating the invi-
tation as well as scheduling an appointment.
Evaluation procedure
The MemoVie project is based on the following overall
procedure of evaluation (Figure 2):
– The first interview (of about one hour) with a
psychologist specifically trained for this study,
during which are performed: 1) another exhaustive
explanation of the study before the presentation of
the informed consent form for signature, 2) the
collection of information on the social and cultural
lifestyle of the participant, 3) the first part of the
neuropsychological tests (see Neuropsychological
evaluation).
– The second interview with the same psychologist
(± one hour), performed more than 1 week after the
first one, and less than 6 months from it, during
which: 1) the informed consent form is signed when
Figure 1 Constitution of the MemoVie cohort. The sample resulting from the 1st part of the study should be at least composed of cognitively
normal people, MCI and AD (grey circle). This sample should allow the prevalence and case-control studies. Arrows depict the different situations/
evolutions occurring over time. The dotted line shows a potential critical situation due to wrong classification of MCI. The sample resulting from
the 2nd part of the study should offer the opportunity to obtain the incidence of MCI and/or AD as well as the progression rate between stages.
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first interview, 2) the neuropsychological tests are
completed, 3) an evaluation of linguistic abilities is
performed.
– The third interview (± 45 minutes), performed by a
trained research nurse, during which participants
undergo a health evaluation and risk factor assessment
(including physiological and anthropological
measurements, see Research nurse evaluation).
After these three interviews, participants are either
suspected of cognitive impairment (CI) or free of cogni-
tive disorders (see Internal classification committee). All
the participants suspected of CI and a matcheda control
group then meet one of the 6 physicians participating inFigure 2 Conduct of the study. CC: cognitive complaint, CI: cognitive imthis project. Thus, a second phase of the protocol
includes, for some participants only:
– A fourth interview (30 to 45 minutes) with a
neurologist or a geriatrician, specifically trained for
this study, who can rely on the neuropsychological
findings and all the observations from the nurse.
This neurogeriatric examination allows completing
the medical anamnesis and providing the final
diagnosis (see External classification). Various tests
are also conducted, mostly to assess the mobility of
participants in walking and balance, but also their
risk of falling (see Neurogeriatric assessment). Gait
and balance assessment may indeed augment the
diagnostic evaluation of dementia [10].pairment.
Table 1 Summary of the tools used for the
neuropsychological evaluation
CERAD-NP:
Verbal semantic fluency (animals)
Modified Boston Naming Test [14]:
denomination test from simple line
drawings
Mini Mental State Exam (MMSE) [15]
Word List Memory (progressive
learning of a 10-item list,
direct recall, learning performance













Letter Cancellation D2 Test
RL/RI-16
Geriatric depression Scale (GDS)
Beck Anxiety Inventory (BAI)
Cognitive Difficulties Scale (CDS)
Clock-Drawing Test (CDT)
Frontal Assessment Battery (FAB)
Informant Questionnaire on




Perquin et al. BMC Public Health 2012, 12:519 Page 5 of 10
http://www.biomedcentral.com/1471-2458/12/1/519– A fifth meeting between the participants and the
trained research nurse (20 minutes) allows closing
the protocol with a blood sample collection and an
evaluation of the olfactory function, the
performance of which decreases in the earliest signs
of age-related neurodegenerative disorders [11].
Site of investigation
The in-person evaluation is proposed and carried out: 1) as
far as possible in a “neutral” place (the Centre for Clinical
and Epidemiological Investigation, CIEC, CRP-Santé ,
Luxembourg) in order to minimize possible environmental
interferences; or 2) at home, taking care to specify the ne-
cessary optimal conditions (quietness, minimized disturb-
ance). The choice of the place is left to the participants,
with the aim of not excluding people who prefer to remain
at home or who experience difficulties in moving. The vari-
ous institutions hosting some participants (homes, inte-
grated centers for the elderly, nursing homes, etc.)
constitute another type of investigation site. Thus, psychol-
ogists and the nurse, as well as the two geriatricians who
are jointly responsible for the appointments at home, visit
these places. The four other neurologists participating in
the study perform their interviews at the CIEC.
Neuropsychological evaluation
The psychologist collects demographic information
including date and place of birth, marital and parental
status. Socio-cultural information is explored, as well as
education and professional activity, habitat network, so-
cial behavior, leisure, physical activities, history of falls
and accidents. Subjects are questioned about their previ-
ous consultations with a neurologist or a psychiatrist.
The multilingualism ability of the participants is quanti-
fied through the number of languages practiced fluently,
the age at which the languages were learned, the duration
of the actual practice, the rate of use of each language: at
home, in daily activities outside (i.e. shops, restaurants,
leisure, administrative procedures, transport) and at work.
With her agreement, we adapted to our own purposes the
Language and Social Background Questionnaire [12]
kindly provided by Prof. E. Bialystok.
The neuropsychological tools chosen for this study aim
at approaching cognitive disorders specific to dementia,
especially AD. Additional tests (1) assess CI more specific-
ally associated with MCI conditions, (2) measure potential
psychological states interfering with cognitive performance,
such as depression and anxiety, (3) estimate cognitive com-
plaints and decline from auto- and hetero-evaluation, and
(4) finally appreciate repercussions of the observed deficits
on daily activities.
The testing proposed consists in The Consortium
to Establish a Register for Alzheimer’s Disease-
Neuropsychological Battery (CERAD-NP) and meets allthese criteria [13]. We used the extended version
(CERAD-NP-plus, see Table 1 for recapitulation) which:
A. measures a large variety of cognitive functions
especially episodic memory and attention/executive
functions that are considered among the first to be
altered in AD [16-18], as well as language and spatial
functions, known to be impaired in early dementia as
well (DSM IV criteria [19]), implying cognitive deficits
in addition to memory impairment: subtests Word
List Learning, delayed Word List Recall, Word List
Recognition, Visual Memory Test, Trail Making Test
A & B, Verbal Fluency (phonological, S) in an
acceptable time frame (30-45 minutes); providing
valuable information for screening and diagnosis of
MCI and early AD if interpreted properly [20];
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C. is sensitive to Alzheimer dementia and other forms
of dementia [23];
D. is available in the different languages [24] required
for the project i.e. the different languages spoken in
Luxembourg (2 official languages -French and
German- and 3 languages commonly used, Italian,
Portuguese and English; http://cerad.mc.duke.edu/
or http://www.memoryclinic.ch);
E. has no global score, the subtests are scored
individually, which allows distinct interpretation of
each cognitive function;
F. has a decoding program that is easy and fast to use.
G. In addition to being normalized on patients with AD
(n = 1,094), the Cerad-NP-plus is normalized on
healthy controls (n = 463) [24-26]. It is also classified
for different age groups.
Moreover, remaining within reasonable time for an
interview, we chose to enrich the cognitive evaluation by
using 9 additional tests added to the CERAD-NP-plus:
H. The free and cued recall of the Grober & Buschke
procedure, RL/RI-16 (Rappel Libre/Rappel Indicé à
16 items) which is an episodic verbal memory test
[27], with high sensibility in early dementia; it has
been recently proposed as core feature in diagnosing
AD [28];
I. The Frontal Assessment Battery (FAB) which has
been used to explore executive functions in
dementias with a frontal dysexecutive phenotype.
This test has validity in differentiating fronto-
temporal type of dementia from AD in mildly
demented patients [29-31];
J. The letter-cancellation test D2 [32] which has been
shown to be an independent predictor of conversion
from MCI to AD [33];
K. The Clock-Drawing Test (CDT) which is one of a
set of brief objective measurements included in the
clinical battery to facilitate the clinical diagnosis of
AD without reliance on the neuropsychological test
results, thereby allowing independent evaluation of
the neuropsychological battery [24];
L. The Cognitive Difficulties Scale (CDS) [34] and the
questionnaire of cognitive complaints (Questionnaire
de Plainte Cognitive, QPC [35]) which allow the
psychologist to estimate cognitive complaints and
decline by auto-evaluation;
M.The short form of the Informant Questionnaire on
Cognitive Decline in the elderly (IQ-CODE, [36])
which is administered to a close person designated
by the participant (informant), in order to obtain a
hetero-evaluation of the cognitive decline for this
participant [37].N. The Beck Anxiety Inventory (BAI, [38]) and the
Geriatric Depression Scale (GDS, [39]) which assess
current or previous anxiety and depression.
Research nurse evaluation
A single nurse performs the following overall evaluation
for all the participants. The nurse collects data on major
events in the medical history of the participant and per-
sonal clinical health status (especially chronic diseases:
diabetes, hypertension, cardiovascular and traumatic
antecedents, cancer, depression, quality of sleep etc.),
together with specific aspects of the family’s medical
history. The subjects also report cigarette smoking or
tobacco use, alcohol intake, potential xenobiotic exposure
and overall well-being (perception of health compared to
other individuals of the same age). The name and dose of
all the current medications and long-term prescriptions
are also collected (subjects are instructed to fill in a table
at home, or to bring boxes of current medications for the
appointment).
The degree of autonomy is assessed for the essential
activities of daily living, measured on three levels: “inde-
pendence”, “partial need of aid” and “dependency”,
according to the ADL [40]. The degree of autonomy in
the completion of instrumental activities of daily living is
additionally informed according to the IADL scale [41].
During the same interview, systolic and diastolic blood
pressure (mmHg) as well as heart rate (beats per minute)
are measured three times using a standard sphygmoman-
ometer (MedisanaW). Possible orthostatic hypotension is
evaluated. Standing body height (cm) is measured using a
stadiometer (SecaW 214). Weight (kg) is evaluated with an
electronic scale (SecaW 813). Other anthropometric mea-
surements are evaluated in accordance with good practices
[42], such as waist, hip, arm, head and calf circumferences.
Circumferences of members are measured (cm) using a
seam tape about 1.8 cm wide.
In the second phase, the nurse collects a fasting blood
sample from the antecubital vein of people suspected to
present CI and of those in the control group (see Evalu-
ation procedure). The samples are transported at 10± 2°C,
(1) in less than one hour to the Laboratoire de Biochimie
of the Centre Hospitalier de Luxembourg (CHL) and (2)
in less than 3 hours, to the Life Sciences Research Unit of
the University of Luxembourg, before being prepared for
later analysis and/or frozen, at -20°C. Concomitantly, the
nurse explores hearing and visual deficiencies with a set of
questions and administers the Brief Smell Identification
TestTM (B-SIT, Sensonics Inc.) to perform a smelling
evaluation [43,44].
Internal classification
After the first three interviews, the internal classification
committee, constituted of several members from the
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sion based on the input of each evaluator (the psychologist
and the nurse). They indeed previously give their own
impression on the cognitive status and the overall health
status of the subjects, considering the possible physiological
disturbances observed. The committee consequently draws
a preliminary cognitive status. Data collected from the
CERAD-NP-plus battery at baseline or follow-up are trans-
formed to z-scores of the normative sample of 1,100 cogni-
tively healthy persons [13]. The z-score indicates how
many standard deviations an individual person’s cognitive
score is from the mean of the normative sample. When
z-score > -1.5, persons are judged to have no CI and are
enrolled as “cognitively normal subjects”. The classification
criteria for suspicion of impairment are: deficient partici-
pant performance (i.e. z-score < -2) in ≥ 1 neuropsycho-
logical subtest of the overall battery; or poor participant
performance (i.e. -2< z-score < -1.5) in ≥ 2 neuropsycho-
logical subtests; or poor in one subtest but with objectified
cognitive complaint or psychological symptoms.
Subjects classified positive for suspicion of cognitive or
psychiatric impairment as well as the matched control
group (see Evaluation procedure) are further assessed by
a physician (see Neurogeriatric assessment).
Neurogeriatric assessment
The neurogeriatric examination is performed by neurolo-
gists or by geriatricians who have been specifically trained
for the study. The physicians administer the Unified
Parkinson’s Disease Rating Scale [45-47], the Timed Get-
Up and Go test [48], as well as the Tinetti questionnaire on
balance and falls [49-51]. With an ad-hoc manufactured
device in line with Newton’s work [52], the physicians ad-
minister to participants the Multi-Directional Reach Test, a
reliable and valid screening tool for measuring the limits of
stability in four directions.
Furthermore, the doctors document their findings about
(1) the cognitive complaint of the participant and his/her
family (when one of its members had accompanied the par-
ticipant), (2) the decline reported by the participant him/
herself and his/her family (idem), (3) the potential impact
on activities of daily living related to cognitive decline, (4)
memory and / or other disorders. Finally, based on the
data collected by the nurse and the psychologist as a
whole, as well as their own clinical impression, the physi-
cians draw conclusions on the cognitive state i.e. if not
normal: suspected MCI; suspicion of other disorders
(documented) that can affect cognition, “CI, not demen-
ted"; suspected dementia; probable dementia; assured syn-
drome of dementia).
External classification
To ensure the standardization of the classification, an
external expert (Prof. JF Dartigues) blindly checks thediagnosed cognitive status, subsequent to the full evalu-
ation, by performing a review of the final diagnoses. In
case of discordance, a panel consisting of the study team
and the external expert discusses the final decision with
a view to obtaining a consensus (Figure 2, Classification
committee). The external classification leads to the vali-
dated diagnosis of “absence of CI”, “isolated cognitive
complaint”, “CI without cognitive complaint”, “MCI”,
“dementia”, and “other CI”.
Biological analysis
Biological examinations are performed on the collected
blood samples. The analyses carried out at the CHL are
performed immediately after arrival of the samples: total
cholesterol, high density lipoprotein (HDL-) and low-
density lipoprotein (LDL-) cholesterol, triglycerides, thy-
roid stimulating hormone (TSH), homocysteine, folic
acid and vitamin B12. In the Life Sciences Research Unit,
the samples are prepared for further screening of the
typical pro- and anti-inflammatory cytokines IL-1α,
IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, MCP-1, IFNγ and
TNFα. The rest of the analyses are carried out in the
Laboratoire de Biochimie er Biologie Moléculaire, CHU,
Nancy, France and are performed after a 6-month max-
imum storage period at -20°C. These analyses relate to
the fatty acid profiles of red blood cell membrane phos-
pholipids: (1) saturated fatty acids, such as palmitic
(C16:0) and stearic (C18:0) acids; (2) mono-unsaturated
fatty acids, respectively omega-7 and -9: palmitoleic
(C16:1N-7) and oleic (C18:1N-9) acids and finally (3)
poly-unsaturated fatty acids of omega-3 and omega-6
groups, including alpha-linolenic acid (ALA C18:3 n-3), ei-
cosapentaenoic acid (EPA C20:5 n-3), docosahexaenoic acid
(DHA C22:6 n-3) as well as linoleic acid (LA C18:2 n-6),
arachidonic acid (ARA C20:4 n-6) and docosatetrae-
noic acid (C22:4 n-6). Moreover the vitamin B6
assay is also performed in Nancy to complete the
picture of the blood concentrations of the “trio of
vitamins B6, B9, B12” and the status of the homo-
cysteinemia. Besides these overall analyses, APOE
genetic polymorphism is investigated as well.
Statistical analyses
Descriptive statistics based on means, standard deviations,
percentages, odds ratios (for nested case-control studies)
or relative risks (for cohort study) and 95% confidence
intervals are used to depict the studied population. Poten-
tial confounding factors are investigated in view to include
appropriate adjustments to statistical modeling. A careful
attention is paid to possible biases. A logistic regression
model is used to investigate association between MCI
status and studied parameters. To this end, univariate ana-
lysis (Chi-square, Student t-test, or Mann-Withney test as
appropriate) is carried out in order to select parameters
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proceeded with stepwise backward elimination, requiring
p< 0.05 for significance and starting with a model that
contains all variables. After final selection, interactions be-
tween variables are tested following the same method.
Clinically significant variables are forced into the model.
The Wald chi-square test is used to assess the significance
of variables in the model. The likelihood ratio test is calcu-
lated to estimate the effect of the deletion of a variable
between subsequent models.
As for the cumulative incidence of participants with
normal conditions, MCI or AD, both binomial and rates
(with calculation of person-years in the cohort) are used.
Relative risk (hazard ratio) of MCI and of evolution to
AD are evaluated with the Cox proportional hazard
model using a competing risks approach. Risk factors
are further included in the model by using a model-
building procedure. The results of neuropsychological
testing are continuous data, and therefore, specific statis-
tical procedures adapted to multivariate analysis of con-
tinuous data are used to assess changes over time.
The risk of MCI to AD conversion and the identification
of risk factors for conversion between normal cognition,
MCI and AD are estimated by using Markov processes.
A p-value of <0.05 is considered statistically significant.
All tests are two-tailed. Statistical analyses are carried out
with the statistical package SAS System version 9.2 (SAS
Institute, Cary, North Carolina, USA).
Quality
Training for standardization of the team
At two different levels of the study procedure, i.e. for the
neuropsychological evaluation as well as for the neuroger-
iatric assessment, a group of 2 to 6 different investigators
respectively perform the same exploration. Therefore, in
addition to extremely strict and precise protocols, psy-
chologists as well as neurologists and geriatricians attend
standardization meetings at the beginning.
Process control, traceability and validation of results
Each step of collection, encoding or processing data and
steps for preparing records of results are verified by two
or even three people involved at specific stages of the
control procedure. The encoding of the collected data is
performed via an integral double entry.
Follow-up procedure
A follow-up was included in the original design of the
study. All the enrolled participants will yearly receive a
phone call and a re-explanation of the study and its
follow-up. Except the multilingualism assessment and
the APOE screening, all people will again undergo the
procedure of evaluation described in the protocol of this
study.Ethics
The study is approved and authorized by the National
Research Ethics Committee (CNER) and the National
Commission for Data Protection (CNPD) in Luxembourg.
Signed informed consent is obtained from all participants.
The individual research results (neuropsychological test
results, measures of blood pressure, heart rate, weight and
height as well as blood test results) are returned to the par-
ticipants and/or their general practitioner, if the participant
mentioned it on the informed consent form.Discussion
The MemoVie study has been set up to depict the senior
population of Luxembourg and to identify the conditions
that could promote CI and evolution to AD. This study is
planned to allow a long-term follow-up of the cognitive
status of the population.
Several parameters are investigated, from health profiles
and long-term intake of medications to occupational
habits and socio-economic status. Particular attention is
paid to multilingualism, as it constitutes one of the ori-
ginal aspects of our study. Among the major information
generated by the MemoVie study, we aim to demonstrate
that a set of various beneficial conditions are significantly
linked to weak CI, which might confer a large panel of
strategies to explore with a view to protecting memory.
These conditions could be based on social interactions
and particular habits, especially nutrition which is
explored here through specific blood lipid components.
This aspect could be essential in the setup of preventive
interventions towards the senior population that exhibits
moderate lipid disorders, thereby leading to higher risk of
cardiovascular disease as well as cognitive decline. Indeed,
the cardiovascular component of AD etiology could well
be of high influence on the risk to develop the neurode-
generative disease.
Great amounts of data need to be analyzed in order to
refine the results obtained, by including strategic adjust-
ments, proposing models of several variables and study-
ing the synergistic effects between the different
conditions.
The results of the MemoVie study, more specifically fo-
cused on Luxembourg’s population, should provide insights
to design new efficient approaches for community-level
interventions intended to preserve overall health status and
well-being in the global aging population.Endnotes
aThe control group is constructed gradually to match
with the group of persons suspected of showing CI,
according to (i) age at enrollment, (ii) sex and (iii)
education.
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